Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
BioNTech and partner DualityBio are accelerating the development of their B7-H3 ADC into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). With encouraging phase 1/2 data, the partners are aiming to achieve success with a trial roughly half the size of the competing program from Merck & Co. and Daiichi Sankyo.
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
